Investment Ratings
As per analysts rating in the last 6 months, the recommendation is to HOLD Bal Pharma
-
Master Rating:
-
Bal Pharma has an operating revenue of Rs. 271.84 Cr. on a trailing 12-month basis. An annual revenue growth of 46% is outstanding, Pre-tax margin of 2% needs improvement, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 45%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 12% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 57 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 147 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Bal Pharma Ltd Forecast
Price Estimates
Eps And Sales Estimates
Bal Pharma Ltd Synopsis
NSE-Medical-Diversified
Bal Pharma Ltd belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 249.31 Cr. and Equity Capital is Rs. 14.82 Cr. for the Year ended 31/03/2021. Bal Pharma Ltd. is a Public Limited Listed company incorporated on 19/05/1987 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L85110KA1987PLC008368 and registration number is 008368.-
Market Cap
INR 148.22 Cr
-
Sales
INR 270.59 Cr
-
Shares in Float
0.79 Cr
-
No of Funds
1 K
-
Yield
1%
-
Book Value
1.87
-
U/D Vol Ratio
1.4
-
LTDebt/Equity
30%
-
Alpha
0.18
-
Beta
1.03
| Owner Name | Jun-21 | Mar-21 | Dec-20 |
|---|---|---|---|
| Promoters | 44.84% | 44.98% | 42.45% |
| Foreign Portfolio Investors | 0% | 0% | 0% |
| Individual Investors | 38.37% | 37.31% | 39.06% |
| Others | 16.79% | 17.71% | 18.49% |
| Name | Designation |
|---|---|
| Mr. Shailesh D Siroya | Managing Director |
| Dr. Subba Rao Prasanna | Executive Director |
| Dr. C V Srinivas | Independent Director |
| Mr. Himesh Virupakshaya | Additional Director |
| Mr. H S Venkatesh | Additional Director |
| Ms. Nicloa Neeladri | Additional Director |
Bal Pharma Ltd Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
| INDICATOR | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 67.0027 | 70.6114 | 70.285 | 62.6955 | 64.2759 |
| Operating Expenses Qtr Cr | 60.5968 | 63.5154 | 63.3275 | 56.4655 | 56.8667 |
| Operating Profit Qtr Cr | 6.4059 | 7.096 | 6.9575 | 6.23 | 7.4092 |
| Depreciation Qtr Cr | 1.7152 | 1.6944 | 2.3261 | 1.6354 | 1.8007 |
| Interest Qtr Cr | 2.577 | 2.97 | 3.1218 | 2.8869 | 3.1664 |
| Tax Qtr Cr | -0.0299 | 0.8109 | -1.6971 | 0.7988 | 1.3069 |
| Net Profit Qtr Cr | 3.0548 | 2.1477 | 4.3788 | 1.5494 | 1.5284 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total Revenue Annual Cr | 252.0074 | 174.2882 | 225.8251 | 211.5208 | 229.3312 |
| Operating Expenses Annual Cr | 222.9898 | 163.9222 | 202.7709 | 187.2296 | 205.8222 |
| Operating Profit Annual in Cr | 26.319 | 6.7506 | 20.3085 | 22.6178 | 20.1188 |
| Depreciation Cr | 7.2566 | 7.0265 | 6.115 | 6.728 | 6.4558 |
| Interest Annual Cr | 11.9582 | 12.4157 | 12.5286 | 9.1086 | 8.4627 |
| Tax Annual Cr | 0.6993 | -0.1742 | -2.3494 | 2.5162 | 3.2767 |
| Net Profit Annual Cr | 9.1035 | -8.902 | 6.76 | 5.9384 | 5.3138 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Cash from Operating Activity Annual Cr | 21.5721 | 9.0998 | 12.5718 | 6.3612 | |
| Cash from Investing Activity Annual Cr | -3.1567 | -9.5298 | -15.5907 | -7.9574 | |
| Cash from Financing Annual Activity Cr | -19.9364 | 0.0478 | 3.5332 | 1.7425 | |
| Net Cash Flow Annual Cr | -1.521 | -0.3822 | 0.5143 | 0.1463 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total ShareHolders Funds Annual Cr | 79.3176 | 65.9448 | 76.8595 | 72.234 | 66.5866 |
| Fixed Assets Annual Cr | 52.6515 | 56.2411 | 56.9977 | 58.4955 | 61.4263 |
| Total Non Current Assets Annual Cr | 68.3399 | 66.8409 | 69.7861 | 69.6163 | 68.4927 |
| Total Current Assets Annual Cr | 193.1997 | 172.4723 | 187.3662 | 181.4795 | 150.3517 |
| Total Assets Annual Cr | 261.5396 | 239.3132 | 257.1523 | 251.0958 | 218.8444 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Book Value Per Share Annual Rs | 46.53 | 54.231 | 50.968 | 46.983 | |
| ROE Annual % | -13.49 | 8.79 | 8.22 | 7.98 | |
| ROCE Annual % | 3.36 | 14.84 | 14.91 | 17.66 | |
| Total Debt to Total Equity Annual | - | - | - | - | - |
| EBDIT Annual Margin % | 11.63 | 6.07 | 10.33 | 11.57 | 10.4 |
Bal Pharma Ltd Technicals
EMA & SMA
CURRENT PRICE
100 
(-0.25)
-
- Bullish Moving Averages 13
- Bearish Moving Averages 3
EMA
-
20 Day
98.39
-
50 Day
99.02
-
100 Day
96.67
-
200 Day
89.31
Bal Pharma Ltd Resistance and support
101.79 PIVOT
-
First Resistance
106.47
-
Second Resistance
112.69
-
Third Resistance
117.37
-
First Support
95.57
-
Second Support
90.89
-
Third Support
84.67
-
RSI
52.86
-
MFI
59.29
-
MACD
-0.01
-
MACD signal line
-0.76
Bal Pharma Ltd Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 134,444 | 6,179,046 | 45.96% |
| Week | 326,706 | 17,962,285 | 54.98% |
| 1 Month | 107,945 | 6,188,499 | 57.33% |
| 6 Month | 97,432 | 5,765,057 | 59.17% |
Bal Pharma Ltd Price change analysis
3.9
Over 1 month
Low High 90.8 109.7
6.7
Over 3 month
Low High 90.8 114.4
-8.75
Over 6 months
Low High 87.65 114.4
44.25
Over Year
Low High 49.55 137.95Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|---|---|---|
| J B Chemicals & Pharmaceuticals Ltd | 1,984.75 | 1,665.00 (0.32%) | 2869 |
| Wanbury Ltd | 115.00 | 66.75 (-4.44%) | 1323 |
| Astrazeneca Pharma India Ltd | 4,900.00 | 3,258.10 (2.50%) | 6314 |
| Mangalam Drugs and Organics Ltd | 196.50 | 125.45 (0.56%) | 7747 |
News
BAL PHARMA LTD. - 524824 - Disclosure Of Related Party Trans
We are submitting to the exchange the disclosure of related party transactions on consolidated basis for the half year ended 30/09/2021 draw Read More
BAL PHARMA LTD. - 524824 - Announcement under Regulation 30
We are submitting to the exchange newspaper advertisements of Notice issued to the shareholders of the Company regarding transfer of shares Read More
Bal Pharma Ltd - 524824 - Disclosures under Reg. 29(2) of SE
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 fo Read More
Bal Pharma Consolidated September 2021 Net Sales at Rs 67.17
NULL Read More
Buzzing Stocks: Bal Pharma, Vedanta and other stocks in news
Stocks In News: Check out the companies making the biggest headlines before the opening bell. Read MoreBlogs